Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.00M | $17.49M | $15.94M | $12.85M | $739.63K | $8.07M | $2.71M | $7.26M |
| Cost of Revenue | $5.88M | $2.89M | $2.86M | $3.02M | $237.71K | $807.19K | $121.39K | $319.76K |
| Gross Profit | $8.12M | $14.60M | $13.08M | $9.83M | $501.92K | $7.26M | $2.59M | $6.94M |
| Gross Margin | 58.00% | 83.49% | 82.06% | 76.48% | 67.86% | 90.00% | 95.52% | 95.59% |
| Operating Expenses | $129.41M | $87.98M | $51.85M | $43.63M | $59.59M | $54.09M | $37.45M | $34.97M |
| Operating Income | $-121.29M | $-73.38M | $-38.77M | $-33.80M | $-59.09M | $-46.82M | $-34.87M | $-28.03M |
| Operating Margin | -866.63% | -419.62% | -243.30% | -262.95% | -7989.03% | -580.07% | -1288.08% | -386.16% |
| Net Income | $-130.39M | $-78.50M | $-41.02M | $-34.58M | $-59.76M | $-47.58M | $-53.14M | $-29.15M |
| Net Margin | -931.65% | -448.89% | -257.39% | -269.03% | -8080.11% | -589.48% | -1962.92% | -401.68% |
| EPS (Basic) | $-1.66 | $-1.21 | $-0.67 | $-0.70 | $-1.76 | $-2.51 | $-7.42 | $-3.40 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |